Neuralink has successfully implanted in a second patient its device designed to give paralyzed patients the ability to use digital devices by thinking alone, according to the startup’s owner Elon Musk.
As part of a major reorganization, Vir Biotechnology has discontinued the bulk of its virology work and pivoted to cancer in an exclusive licensing deal with Sanofi.
Synovial sarcoma is a rare form of cancer in which malignant cells develop and form a tumor in soft tissues of the body. Each year, synovial sarcoma affects about 1,000 people in the United States and most often occurs in adult males in their 30s or younger.
In pursuit of Merck’s blockbuster Keytruda, GSK’s Jemperli scored its own broad FDA label expansion, allowing its use in the first-line endometrial cancer regardless of biomarker status.
With an upfront $800 million payment and $325 million in potential milestones, Otsuka Pharmaceutical is acquiring Jnana Therapeutics’ drug discovery platform and rare disease candidate, the companies announced Thursday.
The U.S. Food and Drug Administration’s website lists some doses of Mounjaro and Zepbound as being in limited supply. Mounjaro has been on the FDA’s shortage list since late 2022.